RxDoctor Payments DataLook up a doctor →

Richard Sola, MD

Interventional Cardiology · Safety Harbor, FLNPI 1245228626

Payments from drug & device makers

$258,500in general payments, 2019–2025

Across 564 payments — averaging $458.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$74K
  • Novo Nordisk AS$66K
  • Surmodics, Inc.$42K
  • Angiodynamics, Inc.$22K
  • Atrium Medical Corporation$21K
  • Cardiovascular Systems Inc.$20K
  • plus $13K from 24 others

What the payments were for

  • Travel & lodging$7,43418%
  • Food & beverage$11,70828%
  • Education$770%
  • Other$22,25054%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$258,500 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$263,278
Medicare patients
521
Services billed
3,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$155,005
Repatha SureclickEvolocumab48$38,554
XareltoRivaroxaban33$37,922
BrilintaTicagrelor32$16,489
VascepaIcosapent Ethyl12$2,931
Nebivolol Hcl35$2,894
Ranolazine ErRanolazine13$2,532
ClopidogrelClopidogrel Bisulfate247$2,187
Irbesartan128$1,899
Rosuvastatin Calcium204$1,784
Potassium Chloride56$1,700
Ezetimibe106$1,676
Atorvastatin Calcium127$1,637
Metoprolol Succinate153$1,566
Amlodipine Besylate214$1,161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$155,005107 claims
Johnson & JohnsonXarelto$184$37,92233 claims
AstraZenecaBrilinta$128$16,48932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Safety Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →